Addex Therapeutics Reports Significant FY2025 Net Loss of CHF 6.7M; Cash Dwindles to CHF 1.6M
ADXN sits 31% above its 52-week low of $5.41.
Summary
Addex Therapeutics reported a significant net loss of CHF 6.7 million for FY2025 and a critically low cash balance of CHF 1.6 million, signaling immediate financial pressure despite pipeline progress.
Key Events · Earnings and Guidance · ADXN
-
Significant Net Loss Reported
The company reported a net loss of CHF 6.7 million for the full year 2025, a sharp decline from a net profit of CHF 7.1 million in 2024.
-
Critically Low Cash Position
Cash and cash equivalents decreased to CHF 1.6 million at December 31, 2025, down from CHF 3.3 million in 2024, indicating a very limited cash runway.
-
Pipeline Progress Highlighted
Addex advanced its GABAB PAM chronic cough candidate in preclinical development and regained rights to its Phase 2 mGlu2 PAM asset, ADX71149.
-
Strategic Collaborations and Investments
The company entered an option agreement with Sinntaxis for mGlu5 NAM in brain injury recovery and made a strategic investment in Stalicla SA, building on the Neurosterix spin-out.
Analysis · ADXN · Life Sciences
Addex Therapeutics reported a substantial net loss of CHF 6.7 million for the full year 2025, a significant reversal from a net profit in the prior year. The company's cash and cash equivalents have fallen to a critical CHF 1.6 million as of December 31, 2025, indicating a very short cash runway. This financial position suggests an urgent need for capital, which could lead to highly dilutive financing events given the company's micro-cap status. While the filing also highlights positive preclinical progress for its GABAB PAM chronic cough candidate and the regaining of rights to a Phase 2 mGlu2 PAM asset, these developments are overshadowed by the severe financial distress. Investors should monitor for potential capital raising activities.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADXN was trading at $7.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.